Bausch + Lomb (BLCO) Discontinues BL1107 Phase 2 Glaucoma Trial, Pivots to Geographic Atrophy Treatment
Disappointing Phase 2 Trial Results Lead to Program Termination
Bausch + Lomb (BLCO) has decided to discontinue the development of BL1107, its eye drop candidate for glaucoma, after the Phase 2 trial failed to meet expectations. The trial, which involved 159 patients with primary open-angle glaucoma and ocular hypertension, did not achieve the primary endpoint of improving visual sensitivity at day 28. While earlier Phase 1/2a trials showed promising results, these were not replicated in the larger Phase 2 study, leading to concerns about commercial viability. To avoid further resource allocation, the company has officially announced the termination of the program.
Strategic Risk Mitigation in Ophthalmology R&D Portfolio
Although this represents a setback in the short term, Bausch + Lomb views this decision as part of a broader risk management strategy. As CMO Yehia Hashad stated, success in drug development relies on a diversified portfolio, and this termination allows for strategic resource reallocation. By halting a pipeline that failed to demonstrate efficacy before entering a potentially costly late-stage trial, the company can preserve its R&D budget and focus on other high-value projects.
Rapid Pivot to Geographic Atrophy Implant Therapy
Bausch + Lomb is discontinuing the development of BL1107 eye drops but plans to continue developing other formulations based on the same alpha-2B adrenergic agonist mechanism. This includes WB006, a sustained-release implant for geographic atrophy (GA), which was acquired through the acquisition of Whitecap Biosciences for an upfront payment of $28 million, plus potential milestones and royalties. Utilizing Ripple Therapeutics' controlled-release drug technology, this pipeline is expected to begin clinical trials in 2028.
Shifting Landscape in the High-Unmet-Need Ophthalmology Market
The global glaucoma treatment market is estimated at $7 billion to $9.5 billion annually, with prostaglandin analogs like latanoprost as the standard of care. Bausch + Lomb already has commercial products in this space, such as Vyzulta and Istalol. Geographic atrophy, on the other hand, is a progressive, irreversible condition that leads to vision loss, and is currently addressed by Apellis' Syfovre and Astellas' Izervay, both of which are in a rapidly growing market. This pivot could allow Bausch + Lomb to potentially commercialize the first small-molecule, sustained-release GA implant, offering patients a more convenient alternative and potentially disrupting the market.
Bausch + Lomb's Phase 2 trial failure represents a short-term setback for its eye drop pipeline targeting the $7 billion global glaucoma market. However, considering the $28 million upfront payment for the acquisition of Whitecap Biosciences, the financial impact is likely manageable. In the medium to long term, the company is strategically shifting its focus to WB006, a sustained-release implant for geographic atrophy (GA), with clinical trials planned for 2028. This move aims to position Bausch + Lomb as a potential competitor in the rapidly growing GA market, currently dominated by Apellis' Syfovre and other early entrants. From a research perspective, a key question remains: can the same alpha-2B adrenergic agonist mechanism demonstrate therapeutic efficacy in a sustained-release implant format, after failing to improve visual sensitivity in a topical eye drop formulation? Investors will need to monitor the progress of WB006's clinical trials and the collaboration with Ripple Therapeutics to assess the potential of Bausch + Lomb's ophthalmology portfolio.